Fushine(SZ:300497) Zheng Quan Ri Bao Wang·2025-10-28 11:45Core Insights - Fuxiang Pharmaceutical reported a revenue of 769 million yuan for the first three quarters of 2025, focusing on the synergistic development of its three core businesses: pharmaceutical manufacturing, new energy lithium battery materials, and synthetic biological microbial proteins [1] R&D Foundation - In the pharmaceutical manufacturing sector, the company is enhancing product potential through green alternatives and process optimizations, leading to a continuous decrease in production costs [2] - The company has achieved a production capacity of 8,000 tons of vinyl carbonate (VC) and 3,700 tons of fluorinated ethylene carbonate (FEC) in its new energy segment, benefiting from a recovering market for electrolyte additives, with prices rising over 20% month-on-month [2] Marketing Expansion - Fuxiang Pharmaceutical is strengthening strategic partnerships with core customers and expanding into international markets, particularly in the synthetic biological microbial protein sector [4] - The establishment of the Weiran Alliance in Shanghai aims to commercialize new protein products and has attracted several international brands as initial members [4] International Market Development - The company has secured a patent in South Korea for its application of short-handled fungus in producing mycelium protein, laying a solid foundation for entering the East Asian market [5] - Fuxiang Pharmaceutical has established a subsidiary in Singapore to focus on the development and sales of microbial protein consumer products, accelerating its overseas market expansion [5][6] Future Outlook - The company plans to continue investing in R&D innovation, enhancing marketing networks, and deepening collaborative innovation with strategic partners to activate new growth momentum [6]